港股收評:恒指跌0.34%失守24000點,創新藥概念股回調,腦機接口飆升
港股三大指數集體收跌,恒生指數跌0.34%再度失守24000點關口,國企指數、恒生科技指數分別下跌0.4%及0.15%,儘管地緣政治有緩和跡象,市場仍未能繼續昨日上升行情。盤面上,大型科技股升跌各異,阿里巴巴升1.68%,騰訊、京東升幅在0.8%以內,百度、小米、美團小幅下跌;前期持續上升的創新藥概念股大幅走低,其中。綠葉製藥跌11%,先聲醫藥跌10.5%,三生製藥、諾誠健華、遠大醫藥、再鼎醫藥等多股跌超7%以上;市場憧憬以伊衝突緩和,黃金股、石油股、軍工股等避險板塊集體回調。另一方面,隔夜美股腦再生科技飆升283.12%,助推港股腦機概念股走高,南京熊貓電子飆升38%表現搶眼,腦洞科技、微創腦科學跟升;花旗上調澳門6月賭收預測至190億澳門元,濠賭股上升明顯,5月iPhone在華銷量居首,蘋果概念股拉昇。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.